Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Asset Writedowns and Impairment (2023 - 2026)

Usana Health Sciences (USNA) has disclosed Asset Writedowns and Impairment for 4 consecutive years, with $370000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Asset Writedowns and Impairment fell 1.86% to $370000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $2.4 million, a 74.77% increase, with the full-year FY2024 number at $1.9 million, down 27.3% from a year prior.
  • Asset Writedowns and Impairment was $370000.0 for Q3 2025 at Usana Health Sciences, down from $834000.0 in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $2.3 million in Q2 2023 to a low of -$506000.0 in Q4 2023.
  • A 3-year average of $627909.1 and a median of $423000.0 in 2023 define the central range for Asset Writedowns and Impairment.
  • Biggest YoY gain for Asset Writedowns and Impairment was 100.4% in 2024; the steepest drop was 59.11% in 2024.
  • Usana Health Sciences' Asset Writedowns and Impairment stood at -$506000.0 in 2023, then surged by 100.4% to $2000.0 in 2024, then surged by 18400.0% to $370000.0 in 2025.
  • Per Business Quant, the three most recent readings for USNA's Asset Writedowns and Impairment are $370000.0 (Q3 2025), $834000.0 (Q2 2025), and $1.2 million (Q1 2025).